44PGlobal clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab. (25th November 2018) - Zhang, Q; Xu, B; Zhang, Q; Sun, T; Li, W; Teng, Y; Hu, X; Bondarenko, I; Adamchuk, H; Zhang, L; Trukhin, D; Wang, S; et al.